{"id":14016,"date":"2025-11-05T21:40:53","date_gmt":"2025-11-05T13:40:53","guid":{"rendered":"https:\/\/zoomax.com\/?p=14016"},"modified":"2026-03-03T14:44:47","modified_gmt":"2026-03-03T06:44:47","slug":"breakthroughs-in-age-related-macular-degeneration-treatment-bridging-new-therapies-with-low-vision-solutions","status":"publish","type":"post","link":"https:\/\/zoomax.com\/ko\/\ub178\ud654-\uad00\ub828-\ud669\ubc18\ubcc0\uc131-\uce58\ub8cc\uc758-\ud68d\uae30\uc801\uc778-\ubc1c\uc804\uc73c\ub85c-\uc0c8\ub85c\/","title":{"rendered":"\uc5f0\ub839 \uad00\ub828 \ud669\ubc18\ubcc0\uc131 \uce58\ub8cc\uc758 \ud68d\uae30\uc801\uc778 \ubc1c\uc804: \uc0c8\ub85c\uc6b4 \uce58\ub8cc\ubc95\uacfc \uc800\uc2dc\ub825 \uc194\ub8e8\uc158\uc758 \uc5f0\uacb0\uace0\ub9ac"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Age-related macular degeneration (AMD) stands as a leading cause of irreversible vision loss worldwide, affecting over 200 million people globally\u2014and that number is projected to rise as populations age. For decades, AMD patients, particularly those with the dry form that accounts for 85-90% of cases, faced a bleak prognosis: gradual central vision loss leading to low vision or even legal blindness, with limited treatment options to halt or reverse the damage. However, 2025 has marked a transformative year in AMD care, with groundbreaking therapeutic technologies emerging alongside advanced \uc800\uc2dc\ub825 \ubcf4\uc870 \uc7a5\uce58<\/a> and electronic magnifiers that empower patients to maintain independence. This article explores the latest AMD treatment innovations, the critical role of low vision support, and how devices like Zoomax<\/a>\u2019s LUNA 6, SNOW 12, and LUNA EYE are bridging the gap between medical progress and daily functionality.<\/p>

Understanding AMD and the Low Vision Crisis<\/h2>

To grasp the impact of new treatments, it\u2019s essential to first recognize the link between AMD and low vision. Low vision is defined as a permanent visual impairment that cannot be corrected by glasses, contact lenses, surgery, or medication, yet leaves some residual sight that can be enhanced with assistive tools. For AMD patients, this manifests as progressive central vision loss\u2014blurry or distorted “blank spots” in the center of their field of view\u2014while peripheral vision often remains intact. The result is a loss of ability to read, recognize faces, drive, or perform daily tasks like cooking or managing finances\u2014activities most people take for granted.<\/p>

\"wet<\/p>

Dry AMD, the more common subtype, involves the slow degeneration of retinal photoreceptor cells in the macula, the part of the eye responsible for sharp central vision. Until recently, treatments focused on slowing progression rather than restoring function, leaving millions reliant on low vision aids (low vision assistive devices) to navigate life. Wet AMD, though less prevalent, progresses faster due to abnormal blood vessel growth under the retina, but has seen more treatment options with anti-VEGF medications. However, even with these therapies, many patients still develop low vision, highlighting the need for both medical breakthroughs and effective assistive technology.<\/p>

The crisis extends beyond physical limitations: low vision from AMD is associated with increased rates of depression, social isolation, and loss of quality of life. This is why the convergence of new AMD treatments and advanced electronic low vision aids is so revolutionary\u2014it addresses both the root cause of vision loss and the immediate functional needs of patients, creating a more holistic approach to care. For those already grappling with vision decline, understanding how to mana<\/em>ge low vision from macular degeneration becomes a critical part of their journey, blending medical intervention with practical tools that turn daily challenges into manageable tasks.<\/p>

2025\u2019s Game-Changing AMD Treatment Technologies<\/h2>

After years of research, 2025 has witnessed four landmark innovations that are redefining AMD treatment, moving from “managing decline” to “restoring function.” These technologies target different stages of AMD, offering hope for both early and advanced cases.<\/p>

PRIMA Retinal Implants: Restoring Vision for Advanced Dry AMD<\/h3>

In October 2025, a study published in The New England Journal of Medicine unveiled the PRIMA (Photovoltaic Retinal Implant Microarray) system, a breakthrough for patients with advanced dry AMD and geographic atrophy. The system consists of a tiny 2mm\u00d72mm wireless implant placed under the retina, paired with specialized glasses and a portable processor. Unlike traditional retinal implants, PRIMA is powered by light, eliminating the need for batteries or wired connections.<\/p>

\"primaIn a clinical trial of 38 patients, 81% experienced clinically significant vision improvement after 12 months\u2014equivalent to reading two more lines on a standard eye chart . Most patients regained the ability to read words, recognize faces, and perform daily tasks they had abandoned due to low vision. While 81% of participants reported temporary severe adverse events (mostly within the first two months post-surgery), 95% of these resolved quickly, and the implant did not harm peripheral vision. The PRIMA retinal implant success rate underscores its potential as a viable option for those with end-stage dry AMD, though it requires careful patient selection and post-operative care.<\/p>

For patients transitioning from advanced low vision to partial vision restoration, PRIMA represents a paradigm shift. However, the system requires months of training to master, and during this adaptation period, low vision electronic magnifiers<\/a> \uff08electronic low vision devices) remain critical. Many PRIMA patients continue to use portable magnifiers like Zoomax\u2019s LUNA 6<\/a> for tasks requiring precise close-up vision, such as reading small print or filling out forms, while relying on the implant for broader visual tasks.<\/p>

Finnish Thermal Therapy: A Minimally Invasive Option for Early Dry AMD<\/h3>

In November 2025, Finnish researchers at Aalto University announced a novel thermal therapy for early-stage dry AMD, offering a non-surgical alternative to slow or reverse cell damage. The therapy uses near-infrared light to gently heat retinal tissue, activating heat shock proteins and cellular autophagy\u2014the body\u2019s natural process for repairing damaged cells. Unlike invasive surgeries, this treatment is non-contact, painless, and targets only affected areas, preserving healthy retinal tissue.<\/p>

\"finnishValidated in animal models (mice and pigs), the thermal therapy has shown promise in halting photoreceptor cell loss and even restoring some function. Clinical trials in humans are set to launch in spring 2026, with expectations of FDA approval within three years. Dry <\/em>AMD treatment 2025 now offers a minimally invasive option, reducing the risk of low vision progression for those in the early stages. For patients in the early stages of AMD, this therapy could prevent the progression to low vision entirely, reducing the need for long-term reliance on low vision aids. For those already experiencing mild low vision, combining thermal therapy with devices like Zoomax\u2019s SNOW 12<\/a>-an advanced 12-inch electronic magnifier with customized user-friendly features-can help maintain quality of life while the treatment takes effect.<\/p>

IPS Cell Retinal Transplants: Regenerating Healthy Tissue<\/h3>

In September 2025, Japanese surgeons in Kobe performed the world\u2019s first successful retinal transplant using induced pluripotent stem (IPS) cells, a milestone for late-stage AMD patients. IPS cells\u2014derived from the patient\u2019s own skin or blood-are reprogrammed to develop into healthy retinal pigment epithelial (RPE) cells, which are then transplanted into the eye to replace damaged cells in the macula.<\/p>

\"ipsThe first patient, a woman with advanced AMD, experienced stable vision improvement within months of the surgery, regaining the ability to navigate independently and read with minimal assistance. This breakthrough offers a “regenerative” approach to AMD treatment, addressing the root cause of vision loss rather than just managing symptoms. IPS cell therapy for AMD is reshaping the prognosis for late-stage patients, even those with long-term low vision, by restoring the retinal tissue that enables central vision. For patients who have lived with severe low vision for years, IPS cell therapy could reduce their dependence on high-powered electronic magnifiers, though many may still use devices like Zoomax\u2019s LUNA EYE<\/a>\u2014a desktop video magnifier with flexible viewing modes-for tasks requiring sustained close-up vision, such as reading books or working on a computer.<\/p>

5G-Powered Robotic Surgery: Precision for Wet AMD and Macular Hemorrhage<\/h3>

While dry AMD has dominated recent breakthroughs, wet AMD and related conditions like macular hemorrhage have seen their own innovation: 5G-enabled robotic surgery. In November 2025, a team from Sun Yat-sen University\u2019s Zhongshan Ophthalmic Center performed the world\u2019s first remote robotic subretinal injection using a domestically developed 5G ophthalmic robot. This procedure is critical for treating wet AMD, macular edema, and macular hemorrhage-conditions that can cause rapid low vision if not treated promptly.<\/p>

\"5g<\/p>

The robot\u2019s 5G connection ensures zero latency, allowing surgeons to perform precise injections from miles away, expanding access to specialized care for patients in rural or underserved areas. For patients recovering from robotic surgery, low vision aids (low vision assistive devices) play a key role in post-operative rehabilitation. The Zoomax \uc2a4\ub178\uc6b0 12<\/a>, with its high-contrast display and compatibility with distance-viewing camer SNOW Eye<\/a>, helps patients adjust to improved vision while reducing eye strain during recovery.<\/p>

The Indispensable Role of Low Vision Aids in AMD Care<\/h2>

While new therapies offer unprecedented hope, low vision aids and electronic magnifiers remain essential components of AMD care-for three key reasons. First, many patients with advanced AMD will not be eligible for the latest treatments (e.g., due to health conditions or severity of retinal damage) and rely entirely on assistive devices. Second, even patients undergoing breakthrough therapies often need low vision tools during treatment, recovery, or adaptation periods. Third, assistive technology enhances the benefits of medical treatments, allowing patients to maximize their restored vision for daily tasks.<\/p>

Key Features of Effective Low Vision Electronic Aids<\/h3>

Modern electronic low vision devices have evolved far beyond basic magnifying glasses, incorporating advanced cameras, high-resolution displays, and user-friendly designs to meet the unique needs of AMD patients. Critical features include:<\/p>